MRK vs OMDA
Merck & Co. vs Omada Health — AI-powered side-by-side comparison
| Metric | MRK | OMDA |
|---|
| AI Score |
70
|
59
|
| Price |
$130.34
|
$24.00
|
| P/E Ratio |
103.53×
|
353.61×
|
| ROE |
34.7%
|
-5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
68.2%
|
| Debt / Equity |
1.29×
|
0.00×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
64.5
|
66.6
|
| Beta |
0.207
|
1.7204
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus OMDA.
MRK leads by 11 points.
MRK scores 70/100 (Buy) versus OMDA at 59/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
OMDA Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 35.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Bollinger bandwidth of 35.5% signals elevated volatility — Risk